quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 14, 2026

BNP highlights bullish takeaways on agentic AI, growth in meetings with Salesforce, Workday, Snowflake

View original at seekingalpha.com
BNP highlights bullish takeaways on agentic AI, growth in meetings with Salesforce, Workday, Snowflake [Humans are using laptops and computers to interact with AI, helping them create, code, train AI, or analyze big data with fast, cutting-edge technology.] BNP Paribas highlighted key takeaways, including agentic AI, g…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce is doing all of the right things, but the share price will not likely react until Salesforce can 1) demonstrate stability in its core business and 2) demonstrate continued success and adoption of Agentforce along with Data Cloud

    60% confidence
  • Competition from Databricks is not new, and competitive fears appear to have died down from their peak a couple of years ago

    60% confidence
  • Data Cloud offering expected to ramp in second half, charged on consumption basis based on data amount

    60% confidence
  • Salesforce has not seen any mass piping of data out of Salesforce to date

    60% confidence
  • Workday is returning to an organic product focus with a goal of delivering revenue growth acceleration, which may result in improved Bookings growth in H2 FY'27 and revenue growth acceleration in FY'28

    60% confidence
  • Flex Credit revenues expected to start ramping up in fiscal year 2027 for new agentic offerings on outcome-based pricing

    60% confidence
  • LLM costs will weigh on gross margins, but Salesforce can secure volume discounts and expects costs per token to come down over time

    60% confidence
  • LLM costs will weigh on gross margins, but Salesforce can secure volume discounts and expects costs per token to come down over time

    60% confidence
  • Salesforce benefits from customer data and metadata context, resulting in better and more accurate outcomes for agentic AI

    60% confidence
  • LLM costs will weigh on gross margins, but Salesforce can secure volume discounts and expects costs per token to decline over time

    60% confidence
  • Marketing business will stabilize with new product functionality ramping, but Commerce taking longer to improve due to competitive pressures and R&D resource allocation to AI

    60% confidence
  • AI native revenues are likely less than 2% of total revenues but may have already helped drive the Q4 beat

    60% confidence
  • LLM companies appear more focused on disrupting the applications market rather than entering data platform market

    60% confidence
  • Marketing business will stabilize with new product functionality ramping, but Commerce taking longer to demonstrate improvements due to competitive pressures and R&D resource allocation

    60% confidence
  • Workday used to generate 60% of growth through existing customer base and 40% through new customers, but new customer growth has slowed in SLED, Healthcare, and retail sectors

    60% confidence
  • 27 years of operational CRM data embedded within systems of record provides advantage versus new competitors

    60% confidence
  • Workday is returning to organic product focus with goal of delivering revenue growth acceleration, potentially improving Bookings growth in H2 FY'27 and revenue growth acceleration in FY'28

    60% confidence
  • Some customers already replacing third-party point solution application functionality by running workflows directly in Snowflake

    60% confidence
  • Workday Data Cloud offering is expected to ramp up in the second half and will be charged on consumption basis based on amount of data

    60% confidence
  • Margin targets may be lowered as company focuses on accelerating top-line growth and ensuring product portfolio is relevant in upcoming Agentic AI world

    60% confidence
  • Snowflake is committed to maintaining product gross margins at 75% this year despite AI product margin headwind

    60% confidence
  • Competition from Databricks is not new, and competitive fears appear to have died down from their peak a couple of years ago

    60% confidence
  • If successful with new initiatives, second-half bookings should show improvement, potentially delivering revenue growth inflection in fiscal year 2027

    60% confidence
  • AI is an opportunity to increase accessibility of Snowflake technologies to more business users beyond just business and data analysts by putting tools like CoCo in people's hands

    60% confidence
  • Company has not seen any mass piping of data out of Salesforce to date

    60% confidence
  • AI native revenue is likely less than 2% but may have already helped drive Q4 beat

    60% confidence
  • Workday's integrated data model across HCM and Finance provides advantage as it increasingly sells the full suite

    60% confidence
  • LLM companies like Anthropic and OpenAI appear more focused on disrupting the applications market rather than entering the data platform market

    60% confidence
  • Salesforce's 27 years of operational CRM data embedded within its systems of record provides advantage versus both startup competitors and DIY approaches

    60% confidence
  • Customers finding value in using Snowflake's own coding tool for data operations because it better identifies patterns and context within Snowflake data while benefiting from Snowflake security and governance

    60% confidence

Data points we hold from this source

Snowflake Inc. · gross margin target75 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com